Form 4: CEO Alise Reicin Sells TECX Shares for Tax Obligations

Tectonic Therapeutic CEO Alise Reicin disposed of 4,104 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Alise Reicin, Chief Executive Officer and Director of Tectonic Therapeutic, Inc. (TECX), reported a transaction on February 4, 2026.
• The transaction involved the disposition of 4,104 shares of TECX common stock at a price of $23.22 per share.
• This disposition was a tax withholding (Transaction Code F) to satisfy tax obligations in connection with the vesting and settlement of restricted stock units (RSUs) granted on February 4, 2025.
• Following this transaction, Ms. Reicin directly beneficially owns 235,047 shares of common stock.
• An additional 124,530 shares are indirectly held by the Reicin-Boiarsky Family Trust, where Ms. Reicin's spouse is a co-trustee.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a mandatory tax-related disposition of shares following RSU vesting, which is a common and expected occurrence for executive compensation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insiders' transactions, particularly for tax-related dispositions following RSU vesting, which is a common compensation practice across various industries, including biotech. This specific filing does not provide broader industry insights.

Related Party Transactions

• Alise Reicin's spouse is a co-trustee of the Reicin-Boiarsky Family Trust, which indirectly holds 124,530 shares of Tectonic Therapeutic common stock. Ms. Reicin disclaims beneficial ownership of these shares except to the extent of her pecuniary interest.

Stakeholder Impact

• No significant direct impact on shareholders, as the transaction is a routine tax-related disposition of shares following RSU vesting and does not reflect a discretionary sale.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary disposition of shares by the CEO for tax withholding purposes related to RSU vesting. It does not indicate any change in the company's fundamentals or the insider's confidence, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Tectonic Therapeutic, TECX, Alise Reicin, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, CEO, Director